622 related articles for article (PubMed ID: 30187471)
1. Antigens and Antibodies in Disease With Specifics About CGRP Immunology.
Taylor FR
Headache; 2018 Nov; 58 Suppl 3():230-237. PubMed ID: 30187471
[TBL] [Abstract][Full Text] [Related]
2. CGRP, Amylin, Immunology, and Headache Medicine.
Taylor FR
Headache; 2019 Jan; 59(1):131-150. PubMed ID: 30390312
[TBL] [Abstract][Full Text] [Related]
3. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L; Haanes KA; Warfvinge K; Krause DN
Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
[TBL] [Abstract][Full Text] [Related]
4. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
Tringali G; Navarra P
Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
[TBL] [Abstract][Full Text] [Related]
5. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
Maasumi K; Michael RL; Rapoport AM
Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
[TBL] [Abstract][Full Text] [Related]
6. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
Hargreaves R; Olesen J
Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
[TBL] [Abstract][Full Text] [Related]
8. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic antibodies against CGRP or its receptor.
Bigal ME; Walter S; Rapoport AM
Br J Clin Pharmacol; 2015 Jun; 79(6):886-95. PubMed ID: 25614243
[TBL] [Abstract][Full Text] [Related]
10. Erenumab in the treatment of migraine.
Jain S; Yuan H; Spare N; Silberstein SD
Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
[TBL] [Abstract][Full Text] [Related]
11. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
[TBL] [Abstract][Full Text] [Related]
12. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.
Cohen F; Yuan H; Silberstein SD
BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215
[TBL] [Abstract][Full Text] [Related]
13. CGRP/CGRP Receptor Antibodies: Potential Adverse Effects Due to Blockade of Neovascularization?
Majima M; Ito Y; Hosono K; Amano H
Trends Pharmacol Sci; 2019 Jan; 40(1):11-21. PubMed ID: 30502971
[TBL] [Abstract][Full Text] [Related]
14. Targeting calcitonin gene-related peptide: a new era in migraine therapy.
Charles A; Pozo-Rosich P
Lancet; 2019 Nov; 394(10210):1765-1774. PubMed ID: 31668411
[TBL] [Abstract][Full Text] [Related]
15. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
16. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
[TBL] [Abstract][Full Text] [Related]
17. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
Bigal ME; Walter S; Rapoport AM
Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
[TBL] [Abstract][Full Text] [Related]
19. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.
Raffaelli B; Reuter U
Neurotherapeutics; 2018 Apr; 15(2):324-335. PubMed ID: 29616494
[TBL] [Abstract][Full Text] [Related]
20. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
Yuan H; Spare NM; Silberstein SD
Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]